Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

Joshua M. Bauml, MD
Published: Friday, Sep 02, 2016


Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses how the approval of pembrolizumab, as well as the use of other immunotherapies, has impacted treatment options for head and neck cancer.
 
Pembrolizumab is going to play a critical role in head and neck cancer, he says. The other agents that are available for the recurrent or metastatic patient population have limited efficacy, and are associated with significant toxicities. This is a clear improvement for this patient population with limited options, he adds.
 
Any patient who has recurrent or metastatic head and neck cancer is going to eventually receive an immunotherapy if they survive long enough, says Bauml. Prior to this approval, there were limited tools in the toolbox for these patients. They had the option of receiving platinum-base chemotherapy and cetuximab, but if they still had recurrent disease after that there were no good options. Many patients had already received cetuximab in the locally advanced setting and had even less options in the recurrent setting, says Baulm. 
 
SELECTED
LANGUAGE

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses how the approval of pembrolizumab, as well as the use of other immunotherapies, has impacted treatment options for head and neck cancer.
 
Pembrolizumab is going to play a critical role in head and neck cancer, he says. The other agents that are available for the recurrent or metastatic patient population have limited efficacy, and are associated with significant toxicities. This is a clear improvement for this patient population with limited options, he adds.
 
Any patient who has recurrent or metastatic head and neck cancer is going to eventually receive an immunotherapy if they survive long enough, says Bauml. Prior to this approval, there were limited tools in the toolbox for these patients. They had the option of receiving platinum-base chemotherapy and cetuximab, but if they still had recurrent disease after that there were no good options. Many patients had already received cetuximab in the locally advanced setting and had even less options in the recurrent setting, says Baulm. 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x